Last update 23 Jan 2025
Emergent Devices, Inc.

Emergent Devices, Inc.

Startups
|
Subsidiary Company|
2014|
Pennsylvania, United States
|
10-50
|
adaptpharma.com

Overview

Basic Info

Introduction
ADAPT Pharma is a pharmaceutical firm that focuses on creating and marketing treatments for patients with unique medical requirements. The company's flagship product is NARCAN (naloxone hydrochloride) Nasal Spray, which is used to treat known or suspected opioid overdose by reversing the effects of opioids on the respiratory and central nervous systems.

Tags

Other Diseases
Small molecule drug

Disease domain score
A glimpse into the focused therapeutic areas
no Data
No Data
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Top 5 Drug TypeCount
Small molecule drug3
Top 5 TargetCount
EGFR(Epidermal growth factor receptor erbB1)1
Opioid receptors1

Related

4
Drugs associated with Emergent Devices, Inc.
Naloxone hydrochloride
Target
μ opioid receptor
Mechanism
μ opioid receptor antagonists
Active Org.
Mundipharma International Ltd.Mundipharma International Ltd. [+11]
Originator Org.
Endo Pharmaceuticals, Inc. [+1]
Active Indication
Opiate Overdose [+2]
Inactive Indication
Pain
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
US
First Approval Date13 Apr 1971
AP-004
Target-
Mechanism-
Active Org.
Emergent Devices, Inc.Emergent Devices, Inc.Startup
Originator Org.
Emergent Devices, Inc.Emergent Devices, Inc.Startup
Active Indication
Opioid-Related Disorders
Inactive Indication-
Drug Highest PhaseClinical
First Approval Ctry. / Loc.-
First Approval Date-
AP-005
Target
EGFR
Mechanism
EGFR modulators
Active Org.
Emergent Devices, Inc.Emergent Devices, Inc.Startup
Originator Org.
Emergent Devices, Inc.Emergent Devices, Inc.Startup
Active Indication
Opioid-Related Disorders
Inactive Indication-
Drug Highest PhaseClinical
First Approval Ctry. / Loc.-
First Approval Date-
100 Clinical Results associated with Emergent Devices, Inc.
Login to view more data
0 Patents (Medical) associated with Emergent Devices, Inc.
Login to view more data
100 Deals associated with Emergent Devices, Inc.
Login to view more data
100 Translational Medicine associated with Emergent Devices, Inc.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Jan 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Preclinical
1
3
Other
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
AP-005
 ( EGFR )		Opioid-Related Disorders
More
Clinical
AP-004
Opioid-Related Disorders
More
Clinical
AP-007
 ( Opioid receptors )		Opioid-Related Disorders
More
Preclinical
Naloxone hydrochloride
 ( μ opioid receptor )		Opiate Overdose
More
Withdrawn
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free